KJ 02
Alternative Names: KJ-02Latest Information Update: 04 Dec 2024
Price :
$50 *
At a glance
- Originator Kiji Therapeutics
- Class Antipsoriatics; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical CNS disorders; Inflammatory bowel diseases; Lung disorders; Psoriasis; Transplant rejection
Most Recent Events
- 18 Oct 2024 Preclinical trials in CNS disorders in France (Parenteral) prior to October 2024 (Kiji Therapeutics Pipeline, October 2024)
- 18 Oct 2024 Preclinical trials in Inflammatory bowel diseases in France (Parenteral) prior to October 2024 (Kiji Therapeutics Pipeline, October 2024)
- 18 Oct 2024 Preclinical trials in Lung disorders in France (Parenteral) prior to October 2024 (Kiji Therapeutics Pipeline, October 2024)